181 related articles for article (PubMed ID: 19828640)
1. PU.1 regulates positive regulatory domain I-binding factor 1/Blimp-1 transcription in lymphoma cells.
Desai S; Bolick SC; Maurin M; Wright KL
J Immunol; 2009 Nov; 183(9):5778-87. PubMed ID: 19828640
[TBL] [Abstract][Full Text] [Related]
2. Identification of a functionally impaired positive regulatory domain I binding factor 1 transcription repressor in myeloma cell lines.
Györy I; Fejér G; Ghosh N; Seto E; Wright KL
J Immunol; 2003 Mar; 170(6):3125-33. PubMed ID: 12626569
[TBL] [Abstract][Full Text] [Related]
3. Positive regulatory domain I (PRDM1) and IRF8/PU.1 counter-regulate MHC class II transactivator (CIITA) expression during dendritic cell maturation.
Smith MA; Wright G; Wu J; Tailor P; Ozato K; Chen X; Wei S; Piskurich JF; Ting JP; Wright KL
J Biol Chem; 2011 Mar; 286(10):7893-7904. PubMed ID: 21216962
[TBL] [Abstract][Full Text] [Related]
4. Positive regulatory domain I-binding factor 1 mediates repression of the MHC class II transactivator (CIITA) type IV promoter.
Chen H; Gilbert CA; Hudson JA; Bolick SC; Wright KL; Piskurich JF
Mol Immunol; 2007 Feb; 44(6):1461-70. PubMed ID: 16765445
[TBL] [Abstract][Full Text] [Related]
5. Blimp-1/PRDM1 regulates the transcription of human CS1 (SLAMF7) gene in NK and B cells.
Kim JR; Mathew SO; Mathew PA
Immunobiology; 2016 Jan; 221(1):31-9. PubMed ID: 26310579
[TBL] [Abstract][Full Text] [Related]
6. Positive regulatory domain I binding factor 1 silences class II transactivator expression in multiple myeloma cells.
Ghosh N; Gyory I; Wright G; Wood J; Wright KL
J Biol Chem; 2001 May; 276(18):15264-8. PubMed ID: 11279146
[TBL] [Abstract][Full Text] [Related]
7. Regulation of B cell linker protein transcription by PU.1 and Spi-B in murine B cell acute lymphoblastic leukemia.
Xu LS; Sokalski KM; Hotke K; Christie DA; Zarnett O; Piskorz J; Thillainadesan G; Torchia J; DeKoter RP
J Immunol; 2012 Oct; 189(7):3347-54. PubMed ID: 22956576
[TBL] [Abstract][Full Text] [Related]
8. Disruption of the B-cell specific transcriptional program in HHV-8 associated primary effusion lymphoma cell lines.
Arguello M; Sgarbanti M; Hernandez E; Mamane Y; Sharma S; Servant M; Lin R; Hiscott J
Oncogene; 2003 Feb; 22(7):964-73. PubMed ID: 12592383
[TBL] [Abstract][Full Text] [Related]
9. PU.1 acts as tumor suppressor for myeloma cells through direct transcriptional repression of IRF4.
Ueno N; Nishimura N; Ueno S; Endo S; Tatetsu H; Hirata S; Hata H; Matsuoka M; Mitsuya H; Okuno Y
Oncogene; 2017 Aug; 36(31):4481-4497. PubMed ID: 28368411
[TBL] [Abstract][Full Text] [Related]
10. PRDM1/Blimp1 downregulates expression of germinal center genes LMO2 and HGAL.
Cubedo E; Maurin M; Jiang X; Lossos IS; Wright KL
FEBS J; 2011 Sep; 278(17):3065-75. PubMed ID: 21722313
[TBL] [Abstract][Full Text] [Related]
11. [Potential mechanism and prognostic value of promoter methylation of PRDM1 gene in diffuse large B cell lymphoma].
Zhang XY; Ma ZP; Cui WL; Chen R; Glinaer A; Miao N; Li XX
Zhonghua Bing Li Xue Za Zhi; 2016 Dec; 45(12):831-837. PubMed ID: 28056297
[No Abstract] [Full Text] [Related]
12. Functional synergism of STAT6 with either NF-kappa B or PU.1 to mediate IL-4-induced activation of IgE germline gene transcription.
Stütz AM; Woisetschläger M
J Immunol; 1999 Oct; 163(8):4383-91. PubMed ID: 10510379
[TBL] [Abstract][Full Text] [Related]
13. Hypermethylation of the tumor suppressor gene PRDM1/Blimp-1 supports a pathogenetic role in EBV-positive Burkitt lymphoma.
Zhang T; Ma J; Nie K; Yan J; Liu Y; Bacchi CE; Queiroga EM; Gualco G; Sample JT; Orazi A; Knowles DM; Tam W
Blood Cancer J; 2014 Nov; 4(11):e261. PubMed ID: 25382611
[TBL] [Abstract][Full Text] [Related]
14. Loss of PRDM1/BLIMP-1 function contributes to poor prognosis of activated B-cell-like diffuse large B-cell lymphoma.
Xia Y; Xu-Monette ZY; Tzankov A; Li X; Manyam GC; Murty V; Bhagat G; Zhang S; Pasqualucci L; Visco C; Dybkaer K; Chiu A; Orazi A; Zu Y; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ponzoni M; Ferreri AJ; Møller MB; Parsons BM; Winter JN; Piris MA; Westin J; Fowler N; Miranda RN; Ok CY; Li Y; Li J; Medeiros LJ; Young KH
Leukemia; 2017 Mar; 31(3):625-636. PubMed ID: 27568520
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA-mediated down-regulation of PRDM1/Blimp-1 in Hodgkin/Reed-Sternberg cells: a potential pathogenetic lesion in Hodgkin lymphomas.
Nie K; Gomez M; Landgraf P; Garcia JF; Liu Y; Tan LH; Chadburn A; Tuschl T; Knowles DM; Tam W
Am J Pathol; 2008 Jul; 173(1):242-52. PubMed ID: 18583325
[TBL] [Abstract][Full Text] [Related]
16. Targeting positive regulatory domain I-binding factor 1 and X box-binding protein 1 transcription factors by multiple myeloma-reactive CTL.
Lotz C; Mutallib SA; Oehlrich N; Liewer U; Ferreira EA; Moos M; Hundemer M; Schneider S; Strand S; Huber C; Goldschmidt H; Theobald M
J Immunol; 2005 Jul; 175(2):1301-9. PubMed ID: 16002735
[TBL] [Abstract][Full Text] [Related]
17. PRDI-BF1/Blimp-1 repression is mediated by corepressors of the Groucho family of proteins.
Ren B; Chee KJ; Kim TH; Maniatis T
Genes Dev; 1999 Jan; 13(1):125-37. PubMed ID: 9887105
[TBL] [Abstract][Full Text] [Related]
18. PRDM1/BLIMP-1 modulates IFN-gamma-dependent control of the MHC class I antigen-processing and peptide-loading pathway.
Doody GM; Stephenson S; McManamy C; Tooze RM
J Immunol; 2007 Dec; 179(11):7614-23. PubMed ID: 18025207
[TBL] [Abstract][Full Text] [Related]
19. MHC class II transactivator (CIITA) expression is upregulated in multiple myeloma cells by IFN-gamma.
Zhao M; Flynt FL; Hong M; Chen H; Gilbert CA; Briley NT; Bolick SC; Wright KL; Piskurich JF
Mol Immunol; 2007 Apr; 44(11):2923-32. PubMed ID: 17300840
[TBL] [Abstract][Full Text] [Related]
20. C/EBPbeta regulates transcription factors critical for proliferation and survival of multiple myeloma cells.
Pal R; Janz M; Galson DL; Gries M; Li S; Jöhrens K; Anagnostopoulos I; Dörken B; Mapara MY; Borghesi L; Kardava L; Roodman GD; Milcarek C; Lentzsch S
Blood; 2009 Oct; 114(18):3890-8. PubMed ID: 19717648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
